Journal Article

Evaluation of <i>CYP2A6</i> genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

Masaki Fujieda, Hiroshi Yamazaki, Tetsuya Saito, Kazuma Kiyotani, Maxwell Afari Gyamfi, Masaharu Sakurai, Hirotoshi Dosaka-Akita, Yuichi Sawamura, Jun Yokota, Hideo Kunitoh and Tetsuya Kamataki

in Carcinogenesis

Volume 25, issue 12, pages 2451-2458
Published in print December 2004 | ISSN: 0143-3334
Published online December 2004 | e-ISSN: 1460-2180 | DOI:
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics


Show Summary Details


We reported previously that subjects homozygous for the cytochrome P450 2A6 (CYP2A6) *4 have a lower risk of lung cancer. The purpose of this study was to clarify whether or not the alterations of smoking behavior and risk for lung cancer could be found in subjects possessing novel CYP2A6 variants discovered recently. An epidemiological study was performed with 1094 cases and 611 controls in male Japanese smokers. It was found that the amounts of daily cigarette consumption in subjects who harbored CYP2A6*4/*7, *4/*10, *7/*7, *7/*9 and *4/*4 genotypes were significantly less than those in subjects carrying the *1/*1 genotype (P < 0.01). Even after adjustment with cigarette consumption, the adjusted odds ratios (ORs) for lung cancer were significantly lower in subjects who harbored CYP2A6*1/*4, *1/*7, *1/*9, *1/*10, *4/*4, *4/*7, *4/*9, *7/*7 and *7/*9 genotypes than those who possessed the *1/*1 genotype (P < 0.05). When participants were classified into four groups according to the CYP2A6 genotypes, group 1 (*1/*1), group 2 (heterozygotes for the *1 and a variant allele), group 3 (heterozygotes and homozygotes for variant alleles except for *4/*4) and group 4 (*4/*4), lung cancer risk was found to be less in subjects with the variant of CYP2A6 alleles {group 2, OR of 0.59 [95% confidence interval (CI), 0.44–0.79]; group 3, OR of 0.52 (95% CI, 0.37–0.72); group 4, OR of 0.30 (95% CI, 0.16–0.57)}. The reduced risk for lung cancer was seen more clearly in heavy smokers than in light smokers. Additional stratification analysis showed that the ORs for squamous cell carcinoma (OR of 0.07) and small cell carcinoma (OR of 0.10) were lower than that of adenocarcinoma (OR of 0.39) in group 4. These results suggest that the CYP2A6 is one of the principal determinants affecting not only smoking behavior but also susceptibility to tobacco-related lung cancer.

Keywords: Ad, adenocarcinoma; CI, confidence interval; NNK, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; OR, odds ratio; SCC, small cell carcinoma; SqCC, squamous cell carcinoma

Journal Article.  6399 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.